Perrigo Company plc (NYSE:PRGO) Declares $0.29 Quarterly Dividend

Perrigo Company plc (NYSE:PRGO) announced a quarterly dividend on Wednesday, April 29th. Shareholders of record on Friday, May 29th will be given a dividend of 0.29 per share on Friday, June 5th. This represents a c) annualized dividend and a yield of 10.3%. The ex-dividend date is Friday, May 29th.

Perrigo has increased its dividend by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 23 consecutive years. Perrigo has a payout ratio of 35.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Perrigo to earn $2.38 per share next year, which means the company should continue to be able to cover its $1.16 annual dividend with an expected future payout ratio of 48.7%.

Perrigo Trading Down 2.0%

PRGO traded down $0.24 during mid-day trading on Wednesday, hitting $11.28. The stock had a trading volume of 1,752,807 shares, compared to its average volume of 3,079,796. The stock’s fifty day simple moving average is $11.29 and its 200-day simple moving average is $13.93. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.76 and a quick ratio of 1.63. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -1.10, a price-to-earnings-growth ratio of 1.35 and a beta of 0.47. Perrigo has a 1-year low of $9.23 and a 1-year high of $28.43.

Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.80 by ($0.03). Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the business posted $0.93 earnings per share. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, research analysts forecast that Perrigo will post 2.12 EPS for the current fiscal year.

Key Perrigo News

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Perrigo’s board approved a quarterly dividend of $0.29 per share (annualized $1.16), implying about a 10.3% yield; record date May 29. A high cash yield can support the share price by attracting income-focused investors. Perrigo Announces Quarterly Dividend
• Positive Sentiment: Zacks moved on Perrigo recently, lifting near-term EPS estimates (Q1 2028 and FY2027/FY2028 upgrades noted) and reporting an upgrade from “strong sell” to “hold” in recent headlines — a marginally more constructive analyst stance that can reduce selling pressure. Zacks Research
• Neutral Sentiment: A Seeking Alpha piece discusses a strategic “thesis reset” for Perrigo — useful for longer-term positioning but not an immediate catalyst. Perrigo: Positioning Through A Thesis Reset
• Neutral Sentiment: Minor reporting inconsistencies on the dividend pay date (one notice lists June 5, PR Newswire lists June 16) — verify settlement/ex-pay dates if dividend timing is a trading consideration.
• Negative Sentiment: Zacks published commentary saying Perrigo lacks the setup for an earnings beat and expects a decline in upcoming earnings — a near-term growth/beat concern that likely weighs on the stock ahead of the report. Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.